Anti-hepatitis B virus efficacy of tenof
β
Yves Benhamou; Herve Fleury; Pascale Trimoulet; Isabelle Pellegrin; Renaud Urbin
π
Article
π
2006
π
John Wiley and Sons
π
English
β 157 KB
for the TECOVIR Study Group Tenofovir disoproxil fumarate (TDF) has shown in vitro activity against both HIV and hepatitis B virus (HBV). We retrospectively evaluated the efficacy of TDF (300 mg/d), administered as a part of anti-retroviral therapy, in a large cohort of HIV/HBV-coinfected patients.